» Articles » PMID: 7189578

Tumor Localization of Radio-labeled Antibodies Against Carcinoembryonic Antigen in Patients with Carcinoma: a Critical Evaluation

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1980 Jul 3
PMID 7189578
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Purified, [131I]-labeled goat antibodies against carcinoembryonic antigen, which have been shown to localize in human carcinoma in nude mice, were injected into 27 patients with carcinoma. Patients were scanned with a scintillation camera at various intervals. In 11 patients, radioactivity was detectable in the tumor 48 hours after injection. Computerized subtraction of blood-pool radioactivity provided clearer pictures in positive cases, but in 16 patients the scans remained doubtful or negative. To study the specificity of [131I]-antibody localization, we gave some patients simultaneous injections of [125I]-labeled normal IgG. Both isotopes were measured by means of scintillation counting in tumors and normal tissues recovered after surgery. The results demonstrated that only the anti-CEA antibodies localized in tumors. However, the total antibody-derived radioactivity in the tumor was only about 0.001 of the injected dose. We conclude that, despite the present demonstration of specificity, this method of tumor detection is not yet clinically useful.

Citing Articles

Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors.

Tolosa E, Yang L, Ayers-Ringler J, Suzuki S, Mallareddy J, Schaefer-Klein J Commun Biol. 2024; 7(1):1719.

PMID: 39741170 PMC: 11688428. DOI: 10.1038/s42003-024-07439-0.


Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies.

Sepp A, Muliaditan M MAbs. 2024; 16(1):2324485.

PMID: 38700511 PMC: 10936618. DOI: 10.1080/19420862.2024.2324485.


Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.

Vahidfar N, Ahmadzadehfar H, Farzanefar S, Abbasi M, Salehi Y, Saboktakin F Curr Radiopharm. 2024; 17(4):320-329.

PMID: 38504563 DOI: 10.2174/0118744710295825240308093429.


Therapeutic Monoclonal Antibodies against Cancer: Present and Future.

Delgado M, Garcia-Sanz J Cells. 2023; 12(24).

PMID: 38132155 PMC: 10741644. DOI: 10.3390/cells12242837.


Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.

Aggarwal D, Yang J, Salam M, Sengupta S, Al-Amin M, Mustafa S Front Immunol. 2023; 14:1203073.

PMID: 37671162 PMC: 10475555. DOI: 10.3389/fimmu.2023.1203073.